Complications associated with erythropoietin-stimulating agents in patients with metastatic breast cancer: A Surveillance, Epidemiology, and End Results-Medicare Study

Cancer

Volumn 117, Issue 16, 2011, Pages 3641-3649

  Chavez Macgregor, Mariana ^a   Zhao, Hui ^b   Fang, Shenying ^b   Srokowski, Tomasz P ^a   Hortobagyi, Gabriel N ^b   Giordano, Sharon H ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

darbepoetin; dose dependency; embolism; erythropoiesis stimulation agent; erythropoietin; ESA; metastatic breast cancer; thrombosis

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTIANEMIC AGENT; NAVELBINE; TAXANE DERIVATIVE;

AGED; ANEMIA; ARTICLE; BLOOD CLOTTING DISORDER; BREAST CANCER; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG SAFETY; FEMALE; HEART INFARCTION; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; METASTATIC BREAST CANCER; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; STROKE; THROMBOEMBOLISM;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; ERYTHROPOIETIN; FEMALE; HUMANS; MEDICARE; NEOPLASM METASTASIS; RETROSPECTIVE STUDIES; SEER PROGRAM; STROKE; THROMBOSIS; UNITED STATES; VENOUS THROMBOSIS;

EID: 80051552235     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25972     Document Type: Article

References (29)

1. Steinbrook R,. Erythropoietin, the FDA, and oncology. N Engl J Med. 2007; 356: 2448-2451. (Pubitemid 46919769)
2. Leyland-Jones B, Semiglazov V, Pawlicki M, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol. 2005; 23: 5960-5972.
3. Vansteenkiste J, Pirker R, Massuti B, et al. Aranesp 980297 Study Group. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst. 2002; 94: 1211-1220. (Pubitemid 34993871)
4. Khuri FR,. Weighing the hazards of erythropoiesis stimulation in patients with cancer. N Engl J Med. 2007; 356: 2445-2448. (Pubitemid 46919767)
5. Bennett CL, Silver SM, Djulbegovic B, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA. 2008; 299: 914-924. (Pubitemid 351397066)
6. Bohlius J, Schmidlin K, Brillant C, et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet. 2009; 373: 1532-1542.
7. Seddighzadeh A, Shetty R, Goldhaber SZ,. Venous thromboembolism in patients with active cancer. Thromb Haemost. 2007; 98: 656-661. (Pubitemid 47412893)
8. Aapro M, Leonard RC, Barnadas A, et al. Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study. J Clin Oncol. 2008; 26: 592-598. (Pubitemid 351264353)
9. Pirker R, Ramlau RA, Schuette W, et al. Safety and efficacy of darbepoetin alpha in previously untreated extensive-stage small-cell lung cancer treated with platinum plus etoposide. J Clin Oncol. 2008; 26: 2342-2349.
10. Rosenzweig MQ, Bender CM, Lucke JP, Yasko JM, Brufsky AM,. The decision to prematurely terminate a trial of R-HuEPO due to thrombotic events. J Pain Symptom Manage. 2004; 27: 185-190. (Pubitemid 38221077)
11. Smith RE Jr, Aapro MS, Ludwig H, et al. Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol. 2008; 26: 1040-1050.
12. NCCN Clinical Practice Guidelines in Oncology. Cancer- and Chemotherapy-Induced Anemia. v.3. 2009. National Comprehensive Cancer Network Web site.
13. Rizzo JD, Somerfield MR, Hagerty KL, et al. American Society of Clinical Oncology; American Society of Hematology. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol. 2008; 26: 132-149.
14. Hellman S,. Stopping metastases at their source. N Engl J Med. 1997; 337: 996-997. (Pubitemid 27425957)
15. Potosky AL, Riley GF, Lubitz JD, Mentnech RM, Kessler LG,. Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care. 1993; 31: 732-748.
16. Klabunde CN, Potosky AL, Legler JM, Warren JL,. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000; 53: 1258-1267. (Pubitemid 32007842)
17. Chew HK, Wun T, Harvey DJ, Zhou H, White RH,. Incidence of venous thromboembolism and the impact on survival in breast cancer patients. J Clin Oncol. 2007; 25: 70-76. (Pubitemid 350003053)
18. Charlson ME, Pompei P, Ales KL, MacKenzie CR,. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40: 373-383. (Pubitemid 17055592)
19. Romano PS, Roos LL, Jollis JG,. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol 1993; 46: 1075-1079; discussion 1081-1090.
20. Aapro M, Scherhag A, Burger HU,. Effect of treatment with epoetin-beta on survival, tumour progression and thromboembolic events in patients with cancer: an updated meta-analysis of 12 randomised controlled studies including 2301 patients. Br J Cancer. 2008; 99: 14-22. (Pubitemid 351920217)
21. Bokemeyer C, Aapro MS, Courdi A, et al. European Organisation for Research and Treatment of Cancer (EORTC) Taskforce for the Elderly. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer. 2007; 43: 258-270. (Pubitemid 46127840)
22. Hershman DL, Buono DL, Malin J, McBride R, Tsai WY, Neugut AI,. Patterns of use and risks associated with erythopoiesis-stimulating agents among Medicare patients with cancer. J Natl Cancer Inst. 2009; 101: 1633-1641.
23. Maschio G,. Erythropoietin and systemic hypertension. Nephrol Dial Transplant. 1995;(10 suppl 2): 74-79.
24. Smith KJ, Bleyer AJ, Little WC, Sane DC,. The cardiovascular effects of erythropoietin. Cardiovasc Res. 2003; 59: 538-548. (Pubitemid 38368670)
25. Pfeffer MA, Burdmann EA, Chen CY, et al. TREAT Investigators. A Trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009; 361: 2019-2032.
26. Roger SD, Fluck RJ, McMahon AC, Raine AE,. Recombinant erythropoietin increases blood pressure in experimental hypertension and uraemia without change in vascular cytosolic calcium. Nephron. 1996; 73: 212-218. (Pubitemid 26159339)
27. Dicato M,. Venous thromboembolic events and erythropoiesis-stimulating agents: an update. Oncologist. 2008;(13 suppl 3): 11-15.
28. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet. 2003; 362: 1255-1260. (Pubitemid 37324251)
29. Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW,. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008; 111: 4902-4907.